MOLyF : Bone Marrow and Follicular Lymphoma

Bone Marrow and Follicular Lymphoma

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06608147

Acronym

MOLyF

Enrollment

200

Registered

2024-09-23

Start date

2024-12-04

Completion date

2034-10-01

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Follicular

Brief summary

This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects. Follicular lymphoma is the most common indolent lymphoma. It is characterised by systematic relapses and bone marrow dissemination in 70% of patients at the time of diagnosis. Although relapses are thought to be related to refractory tumour cells nested in a supportive microenvironment in the bone marrow, the mechanisms involved are poorly understood. To study the specificities of the bone marrow of patients with follicular lymphoma, It is necessary to compare them with control samples. This study takes advantage of surgeries involving sternotomies to recover lost bone marrow and establish a bone marrow bank of patients without hematological disease. This bank will be used to set up control cohorts for other clinical trials involving patients with follicular lymphoma.

Interventions

OTHERSampling

sternal bone marrow aspiration

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Major patient * Patient hospitalized in the thoracic, cardiac and vascular surgery department for surgery involving a sternotomy * Patient with free, informed, written consent * Patient covered by a health insurance scheme

Exclusion criteria

* History of haematological malignancy or haemogram disturbance * Immunomodulating treatment: immunosuppressants, corticoids, antineoplastics * Persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.)\].

Design outcomes

Primary

Measure	Time frame	Description
Flow cytometric quantification of cell populations	1 day	Bone marrow cell populations of lymphoma-free patients (lymphoid cells, myeloid cells, stromal cells and adventitial cells) will be quantified using a flow cytometry panel and compared with those of Follicular Lymphoma patients.

Countries

France

Contacts

Primary ContactJuliette Ferrant, MD

juliette.ferrant@chu-rennes.fr0299282555

Backup ContactAlexandra Guerrier

alexandra.guerrier@chu-rennes.fr0299282555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026